journal article·2015-12

Enhanced anti-tumor efficacy and safety profile of tumor microenvironment-responsive oncolytic adenovirus nanocomplex by systemic administration

Joung-Woo Choi, Kasala Dayananda, Soo-Jung Jung, Soo-Hwan Lee, Donghyun Kim, Jun Hu, You Han Bae, Chae-Ok Yun

Acta Biomaterialia· Volume 28
Publisher page

Abstract

Oncolytic adenovirus (Ad) holds great promise as a potential gene therapy for cancer. However, intravenously administered Ad may encounter difficulties due to unfavorable host responses, non-specific interactions, and the heterogeneity of the tumor cell population. As an approach to combine the advantages of oncolytic Ad and synthetic polymers and to address the associated difficulties, Ad was physically complexed with a pH-sensitive block copolymer, methoxy poly(ethylene glycol)-b-poly(l-histidine) (mPEG-b-pHis). The in vitro transduction efficiency at an acidic extracellular pH was remarkably enhanced in cancer cells when treated with the Ad expressing green fluorescent protein (GFP) coated with mPEG-b-pHis (c-dE1/GFP) as compared to that of naked Ad (n-dE1/GFP). Time-lapse total internal reflection fluorescence microscopic imaging revealed a significantly enhanced cellular uptake rate of c-dE1/GFP at acidic tumor pH when compared with that at neutral pH or naked cognate Ad (n-dE1/GFP). In addition, c-dE1/GFP remained relatively stable in human serum-containing media, and considerably reduced both the innate and adaptive immune response against Ad. Moreover, the therapeutic efficacy and survival benefit of mPEG-b-pHis-complexed oncolytic Ad (c-H5mT/Luc) by systemic treatment was significantly enhanced compared to that with naked oncolytic Ad (n-H5mT/Luc) in both coxsackie and adenovirus receptor-positive and -negative tumors. Whole-body bioluminescence imaging showed 7.3-fold higher luciferase expression at the tumor site and 23.0-fold less luciferase expression in liver tissue for c-H5mT/Luc relative to that for naked oncolytic Ad (n-H5mT/Luc). Considering the heterogeneity of tumor tissue, these results are important for guiding the development of more potent and specific treatment of devastating metastatic cancers using this viral system. Statement of significance Although adenoviral systems have shown considerable promise and undergone extensive evaluation attempts to specifically target Ad vectors to cancer cells have met limited success. This shortcoming is due to the strong immune response stimulated by Ad and the hepatotoxicity of the viral particles. To overcome restricted vector issues, we generated Ad/mPEG-b-pHis for tumor microenvironment-targeting hybrid vector systems, an oncolytic Ad coated with a pH-responsive polymer, mPEG-b-pHis. The Ad/mPEG-b-pHis exhibited pH-dependent transduction efficiency and cancer-cell killing effects. Moreover, systemic administration of oncolytic Ad/mPEG-b-pHis led to marked suppression of tumor growth and tumor-specific viral replication. Ad successfully avoided the innate and adaptive immune responses and liver accumulation with the help of mPEG-b-pHis on its surface.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Virus-based gene therapy research · Cancer Research and Treatments · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (37)

Show source-provided references
1. Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials10.1517/14712598.1.3.525 ↗
2. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer10.1038/78638 ↗
3. Recent progress in the battle between oncolytic viruses and tumours10.1038/nrc1750 ↗
4. Designer adenoviruses for nanomedicine and nanodiagnostics10.1016/j.tibtech.2009.01.003 ↗
5. Current issues and future directions of oncolytic adenoviruses10.1038/mt.2009.266 ↗
6. Cancer gene therapy by adenovirus-mediated gene transfer10.2174/1566523013349002 ↗
7. Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms10.1038/mt.2010.159 ↗
8. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors10.1038/sj.cr.7310032 ↗
9. Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide10.1038/sj.mt.6300321 ↗
10. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo10.1089/10430349950018364 ↗
11. Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol)10.1016/0005-2760(92)90255-T ↗
12. Blood clearance rates of adenovirus type 5 in mice10.1099/0022-1317-81-11-2605 ↗
13. Evolution of oncolytic adenovirus for cancer treatment10.1016/j.addr.2011.12.011 ↗
14. Safety profiles and antitumor efficacy of oncolytic adenovirus coated with bioreducible polymer in the treatment of a CAR negative tumor model10.1021/bm501116x ↗
15. HPMA copolymers for masking and retargeting of therapeutic viruses10.1016/j.addr.2009.12.003 ↗
16. Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies10.1038/sj.mt.6300306 ↗
17. Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy10.1080/10611860701501014 ↗
18. Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus10.1089/hum.2009.028 ↗
19. Tumor vascular targeted delivery of polymer-conjugated adenovirus vector for cancer gene therapy10.1038/mt.2011.112 ↗
20. The effect of surface modification of adenovirus with an arginine-grafted bioreducible polymer on transduction efficiency and immunogenicity in cancer gene therapy10.1016/j.biomaterials.2009.11.043 ↗
21. Bioreducible polymer-conjugated oncolytic adenovirus for hepatoma-specific therapy via systemic administration10.1016/j.biomaterials.2011.08.066 ↗
22. Anionic liposomes increase the efficiency of adenovirus-mediated gene transfer to coxsackie-adenovirus receptor deficient cells10.1021/mp900151k ↗
23. Active targeting of RGD-conjugated bioreducible polymer for delivery of oncolytic adenovirus expressing shRNA against IL-8 mRNA10.1016/j.biomaterials.2011.03.084 ↗
24. Current advances in adenovirus nanocomplexes: more specificity and less immunogenicity10.5483/BMBRep.2010.43.12.781 ↗
25. Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials10.1016/j.biomaterials.2011.11.020 ↗
26. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses10.1016/j.ymthe.2004.09.015 ↗
27. Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and alphav integrin-binding ablation10.1128/JVI.77.24.13062-13072.2003 ↗
28. Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates10.1016/S1525-0016(03)00139-4 ↗
29. Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner10.1089/104303403769211637 ↗
30. Therapeutic targeting of chitosan-PEG-folate-complexed oncolytic adenovirus for active and systemic cancer gene therapy10.1016/j.jconrel.2013.03.030 ↗
31. PH-Sensitive polymeric micelle-based pH probe for detecting and imaging acidic biological environments10.1021/bm300985r ↗
32. Enhanced therapeutic efficacy of an adenovirus-PEI-bile-acid complex in tumors with low coxsackie and adenovirus receptor expression10.1016/j.biomaterials.2014.03.060 ↗
33. Poly(l-histidine)-PEG block copolymer micelles and pH-induced destabilization10.1016/S0168-3659(03)00205-0 ↗
34. PH-induced micelle formation of poly(histidine-co-phenylalanine)-block-poly(ethylene glycol) in aqueous media10.1002/mabi.200500121 ↗
35. Physicochemical characteristics of pH-sensitive poly(l-histidine)-b-poly(ethylene glycol)/poly(l-lactide)-b-poly(ethylene glycol) mixed micelles10.1016/j.jconrel.2007.11.014 ↗
36. Spatiotemporal dynamics of adenovirus membrane rupture and endosomal escape10.1128/JVI.01428-12 ↗
37. Increased hepatic transduction with reduced systemic dissemination and proinflammatory cytokines following hydrodynamic injection of helper-dependent adenoviral vectors10.1016/j.ymthe.2005.03.001 ↗